Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases — Stella

Home/Lupus Erythematosus, Systemic/

View on ClinicalTrials.gov

Recruiting

Back to Lupus Erythematosus, Systemic trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Italy

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio

Key details

Phase

Early testing / Safety & dosing

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Enrollment target

~8 participants

Started

November 2024

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 65 Years

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.